- Home
- TOP vs CUE Comparison
TOP vs CUE Comparison
Compare TOP & CUE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TOP
- CUE
- Stock Information
- Founded
- TOP 2015
- CUE 2014
- Country
- TOP Hong Kong
- CUE United States
- Employees
- TOP N/A
- CUE N/A
- Industry
- TOP Investment Bankers/Brokers/Service
- CUE Biotechnology: Pharmaceutical Preparations
- Sector
- TOP Finance
- CUE Health Care
- Exchange
- TOP Nasdaq
- CUE Nasdaq
- Market Cap
- TOP 62.9M
- CUE 64.4M
- IPO Year
- TOP 2022
- CUE 2018
- Fundamental
- Price
- TOP $1.61
- CUE $1.25
- Analyst Decision
- TOP
- CUE Strong Buy
- Analyst Count
- TOP 0
- CUE 5
- Target Price
- TOP N/A
- CUE $5.00
- AVG Volume (30 Days)
- TOP 142.9K
- CUE 971.4K
- Earning Date
- TOP 11-26-2024
- CUE 11-14-2024
- Dividend Yield
- TOP N/A
- CUE N/A
- EPS Growth
- TOP N/A
- CUE N/A
- EPS
- TOP 0.03
- CUE N/A
- Revenue
- TOP $8,037,105.00
- CUE $9,532,000.00
- Revenue This Year
- TOP N/A
- CUE $104.81
- Revenue Next Year
- TOP N/A
- CUE N/A
- P/E Ratio
- TOP $49.42
- CUE N/A
- Revenue Growth
- TOP N/A
- CUE 149.53
- 52 Week Low
- TOP $1.39
- CUE $0.45
- 52 Week High
- TOP $7.77
- CUE $3.25
- Technical
- Relative Strength Index (RSI)
- TOP 40.87
- CUE 43.10
- Support Level
- TOP $1.62
- CUE $1.32
- Resistance Level
- TOP $1.84
- CUE $1.99
- Average True Range (ATR)
- TOP 0.10
- CUE 0.29
- MACD
- TOP -0.00
- CUE -0.06
- Stochastic Oscillator
- TOP 10.20
- CUE 0.67
About TOP TOP Financial Group Limited
TOP Financial Group Ltd is an online brokerage firm in Hong Kong specializing in trading local and overseas equities, futures, and options products. The Company generates brokerage commission income by enabling its customers to trade on multiple exchanges present globally. The company operates in only one segment which is the futures brokerage service.
About CUE Cue Biopharma Inc.
Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its objective is to provide patients suffering from cancer and autoimmune disease with dramatically improved therapeutic outcomes through the platform of biologic drug product candidates. The other products under pipeline are CUE-101 as a Monotherapy, CUE-101 + Pembrolizumab, CUE-102, CUE-103 and others.